Anser VDZ
Use
Anser VDZ supports the therapeutic drug monitoring of vedolizumab (VDZ) and antibodies-to-VDZ (ATV) levels. This aids in optimizing dosing for effective treatment outcomes in patients using vedolizumab, particularly in managing inflammatory disorders like IBD.
Special Instructions
This test is designed to quantitate both drug and antibody levels using HMSA methods. It is critical for treatment adjustments in clinical practice.
Limitations
The Anser VDZ test remains a laboratory-developed procedure not sanctioned by the FDA. Its clinical application should be within the confines of CLIA-validated practices.
Methodology
Immunoassay (HMSA)
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.0 mL
Minimum Volume
0.5 mL for Peds
Container
Serum Separator Tube or Red-Top Tube
Storage Instructions
Transport ambient or with a cold pack. Do not freeze.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |